Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H18ClN7O |
Molecular Weight | 299.76 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(C(C)C)C1=C(Cl)N=C(C(=O)NC(N)=N)C(N)=N1
InChI
InChIKey=QDERNBXNXJCIQK-UHFFFAOYSA-N
InChI=1S/C11H18ClN7O/c1-4-19(5(2)3)9-7(12)16-6(8(13)17-9)10(20)18-11(14)15/h5H,4H2,1-3H3,(H2,13,17)(H4,14,15,18,20)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15505102Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21978672 | https://www.ncbi.nlm.nih.gov/pubmed/17493937 | https://www.ncbi.nlm.nih.gov/pubmed/28848079 | https://www.ncbi.nlm.nih.gov/pubmed/23075671 | https://www.ncbi.nlm.nih.gov/pubmed/1713995
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15505102
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21978672 | https://www.ncbi.nlm.nih.gov/pubmed/17493937 | https://www.ncbi.nlm.nih.gov/pubmed/28848079 | https://www.ncbi.nlm.nih.gov/pubmed/23075671 | https://www.ncbi.nlm.nih.gov/pubmed/1713995
Ethylisopropylamiloride (5-(N-ethyl-N-isopropyl)-Amiloride, EIPA) is a potent inhibitor of several Sodium-hydrogen exchangers (NHE) isoforms, inhibiting NHE1, NHE2, NHE3, and NHE5, that potentially can be used in cancer treatment. Ethylisopropylamiloride was also demonstrated to inhibit a wide variety of cation channels such as KATP channels) peptide-gated Na+ channels and shrinkage-activated Na+ channels. EIPA is commonly used at a concentration of 5-10 μM to inhibit cellular HNE activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2781 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21978672 |
800.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15505102
Apolipoprotein E null mice (apoE-/-) fed an atherogenic diet received a subcutaneous pump infusion of either EIPA (3 mg/kg/d) or the control vehicle for 4 weeks.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28848079
The nontransformed rat small intestinal epithelial IEC-18 cell line was used for activity evaluation. For the amino acid starvation-induced autophagic cell model, the IEC-18 cells were incubated in Hank’s Balanced Salt Solution (HBSS; Gibco/Invitrogen) as the culture medium for 6 h under the same atmospheric conditions. Then, alanine (1.0 mM final concentration; Sigma-Aldrich) or proline (0.5 mM final concentration, Sigma-Aldrich) with or without the NHE3 inhibitor 5-(N-ethyl-N-isopropyl) amiloride (EIPA; 0.3 mM final concentration; A3085, Sigma-Aldrich) was added to the culture medium and incubated with the cells for 6 h. To identify the optimal concentrations of amino acids (alanine and proline) and EIPA that elicited the best effect, various concentrations were tested. The effect of EIPA alone (without alanine or proline) was also examined in both control (DMEM cultured cells) and amino acid-starved cells. The cells were incubated for 6 h in DMEM containing 5% FBS and either 0 or 0.3 mM EIPA (labelled QNN and QNE, respectively), HBSS containing either 0 or 0.3 mM EIPA (labelled HNN and HNE, respectively), HBSS with 1.0 mM alanine (labelled HAN) or 0.5 mM proline (labelled HPN), HBSS with 1.0 mM alanine and 0.3 mM EIPA (labelled HAE), and HBSS with 0.5 mM proline and 0.3 mM EIPA (labelled HPE). To evaluate the autophagic activity, the autophagosome-lysosome fusion inhibitor chloroquine (CQ; 50 μM; Sigma-Aldrich) was used.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1154-25-2
Created by
admin on Fri Dec 15 19:38:33 GMT 2023 , Edited by admin on Fri Dec 15 19:38:33 GMT 2023
|
PRIMARY | |||
|
1795
Created by
admin on Fri Dec 15 19:38:33 GMT 2023 , Edited by admin on Fri Dec 15 19:38:33 GMT 2023
|
PRIMARY | |||
|
136538
Created by
admin on Fri Dec 15 19:38:33 GMT 2023 , Edited by admin on Fri Dec 15 19:38:33 GMT 2023
|
PRIMARY | |||
|
DTXSID80151084
Created by
admin on Fri Dec 15 19:38:33 GMT 2023 , Edited by admin on Fri Dec 15 19:38:33 GMT 2023
|
PRIMARY | |||
|
VW50CE070T
Created by
admin on Fri Dec 15 19:38:33 GMT 2023 , Edited by admin on Fri Dec 15 19:38:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY